Analysis on the causes of intravenous injection of prostaglandin E1 to phlebitis in patients with liver disease
Objective To analyze the causes and countermeasures of intravenous injection of prostaglandin E1 to phlebitis in patients with liver disease. Methods 562 cases of liver disease patients with venous injection of prostaglandin E1 phlebitis caused by patients in our hospital were retrospectively analyzed from January 2015 to June 2017, in gender, age, time, degree, treatment and outcome were analyzed. Results 51 cases of prostaglandin E1 in patients with phlebitis, 32 cases of male, female 19 cases, the average age was (56±6.7), and phlebitis age distribution mainly in 50 to 59 years old and 60-69 age group, 27.4% and 41.3% respectively. The time of phlebitis occurred mainly in 22 cases, accounting for 43.2%. The degree of occurrence of 51 cases of phlebitis: level 1, 35 cases (68.6%), grade 2, 13 cases (25.5%), 3 cases in 3 cases (5.9%), and grade 4 had no one. 51 cases of phlebitis were regrouped: 44 cases were cured and 7 were better. Conclusion The intravenous injection of prostaglandin E1 in patients with liver disease can cause phlebitis, which can be cured or improved by treatment and treatment, and can be prevented.
NETL
NSTL
万方数据
维普
